MRC1 and cancer: Our study suggests that a cancer vaccine approach could be used either as monotherapy or in combination with established immuno-oncology or chemotherapy drugs, to treat Lynch syndrome patients with mutations in MMR-associated genes and those who have progressed to colon cancer, to prevent relapse and to possibly achieve a cure.